Surmodics (NASDAQ:SRDX) (NASDAQ:SRDX) is a global provider of medical device technologies and contract manufacturing services, with headquarters in Eden Prairie, Minnesota. Since its founding in 1988, the company has developed a diversified portfolio of proprietary surface modification platforms, in vitro diagnostic reagents and surgical imaging agents. Surmodics partners with leading medical device and life sciences companies to enhance device performance and enable new clinical applications.
In the surface modification segment, Surmodics offers hydrophilic, anti-thrombogenic and drug-eluting coatings that improve biocompatibility, reduce friction and permit controlled drug delivery from implants such as stents and catheters. The company also provides contract coating and manufacturing services, leveraging its scalable facilities and quality systems to support commercialization of complex combination products.
Through its imaging reagents division, Surmodics develops near-infrared fluorescent dyes for intraoperative and diagnostic use, supporting surgeons in real-time visualization of tissue structures and tumor margins. These reagents are supplied under development and commercialization partnerships, extending the company’s reach into oncologic and vascular imaging markets.
Surmodics conducts operations and sales across North America, Europe and Asia, serving a broad base of original equipment manufacturers. The company is led by President and Chief Executive Officer Steve W. Anderson, with Chief Financial Officer Thomas Giannini overseeing financial strategy. A seasoned management team and Board of Directors guide strategic growth initiatives and technology innovation.
